




The relative strengths and weaknesses of Keenova Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keenova Therapeutics plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Keenova Therapeutics plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 168% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 134% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	2,309,600	Assets	8,916,300
Cost of Goods Sold	1,317,100	Liabilities	8,602,900
Intangible Assets	5,448,400	Expenses	2,955,400
Liabilities, Current	1,942,200	Revenues	2,208,800
Liabilities, Non-Current	85,800	Stockholders Equity	313,400
Other Assets	382,300	Net Income	-717,400
Other Compr. Net Income	1,300	Comprehensive Net Income	-716,750
Other Expenses	851,300	BaseVar	11,356,950
Other Liabilities	6,574,900	ECR before LimitedLiability	-0.38%
Other Net Income	29,200	Economic Capital Ratio	141%
Other Revenues	2,208,800		
Property and Equipment	776,000		
Research and Development	205,200		
Selling, General and Administrative Expense	581,800		